Trial Profile

A phase I clinical trial to evaluate safety and toxicity of Bryostatin-1 in children and young adults with CD22 + leukemia and B-cell lymphoma

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 27 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Jun 2020 According to BryoLogyx media release, Neurotrope will also transfer to BryoLogyx the Investigational New Drug (IND) application that is in development. BryoLogyx will be responsible for the IND going forward and will pay a nominal fee on gross revenues generated by the commercial sale of bryostatin-1 product sold by BryoLogyx for the treatment of ALL
10 Jun 2020 According to BryoLogyx media release, BryoLogyx announces agreements with Neurotrope to acquire bryostatin-1 immuno-oncology data package and supply synthetic bryostatin-1. Agreements will accelerate BryoLogyxs path to clinical proof-of-concept study
07 Feb 2019 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com